There are currently 603 clinical trials in Omaha, Nebraska looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Nebraska Medical Center, Creighton University Medical Center, Nebraska Methodist Hospital and Alegent Health Bergan Mercy Medical Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Longitudinal Observational Study of Patients Undergoing Therapy for IMISC
NCT03661866
Recruiting
TARGET-DERM is a longitudinal, observational study of adult and pediatric patients being managed for Atopic Dermatitis and other Immune-Mediated Inflammatory Skin Conditions (IMISC) in usual clinical practice. TARGET-DERM will create a research registry of patients with IMISC within academic and community real-world practices in order to assess the safety and effectiveness of current and future therapies.
Gender:
All
Ages:
All
Trial Updated:
03/19/2024
Locations: Advanced Dermatology of the Midlands, Omaha, Nebraska
Conditions: Atopic Dermatitis, Hidradenitis Suppurativa, Vitiligo, Psoriasis, Alopecia Areata, Chronic Spontaneous Urticaria
Register for Updates
Modern Immunotherapy in BCG-Unresponsive, BCG-Relapsing and High Risk BCG-Naive Non-Muscle Invasive Urothelial Carcinoma of the Bladder
NCT03317158
Recruiting
Upon successful screening and registration, enrollment to durvalumab monotherapy (cohort 1) will begin. If DLT criteria outlined in the protocol are exceeded with durvalumab monotherapy (cohort 1), the study will close. Provided the safety of durvalumab monotherapy is established, enrollment to combination regimen cohorts will proceed. Cohorts will simultaneously enroll in parallel to each other with patients assigned to cohorts based on patient slot availability and study site choice of radiati... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/19/2024
Locations: University of Nebraska Medical Center, Omaha, Nebraska
Conditions: Urothelial Carcinoma, Bladder Cancer
Register for Updates
Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer
NCT05425940
Recruiting
This is a multicenter, randomized, open-label, controlled Phase 3 trial of XL092 + atezolizumab vs regorafenib in subjects with microsatellite stable/microsatellite instability low (MSS/MSI-low) metastatic colorectal cancer (mCRC) who have progressed during, after or are intolerant to standard-of-care (SOC) therapy.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/18/2024
Locations: Exelixis Clinical Site #1, Omaha, Nebraska
Conditions: Colorectal Cancer
Register for Updates
Candin for the Treatment of Common Warts
NCT05889845
Recruiting
The goal of this clinical trial is to compare outcome in healthy subjects 12 years of age and older with at least 3, but no more than 20, common warts (Verruca vulgaris) following treatment with Candin or placebo. The main questions it aims to answer are: does treatment with Candin result in better clearance of warts than placebo how many injections are required to result in wart clearance Participants will have one wart selected for injection every two weeks until clearance return 12 weeks aft... Read More
Gender:
All
Ages:
12 years and above
Trial Updated:
03/15/2024
Locations: Schlessinger MD, Omaha, Nebraska
Conditions: Common Warts (Verruca Vulgaris)
Register for Updates
The MS-LINK™ Outcomes Study
NCT04735406
Recruiting
The Multiple Sclerosis (MS) Leadership and Innovation Network (MS-LINK™) is comprised of networks working cooperatively to advance Multiple Sclerosis (MS) science and improve MS participant outcomes. In this study participants will be followed from the time of consent through the lifetime of the study (currently 3 years), unless the participant chooses to withdraw from the study. Collection of participant's medical history, including MS and treatment history, will be automated through extraction... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/15/2024
Locations: University of Nebraska medical Center, Omaha, Nebraska
Conditions: Multiple Sclerosis
Register for Updates
Prophylactic Reinforcement of Ventral Abdominal Incisions Trial
NCT03911700
Recruiting
This trial is being conducted to evaluate the efficacy of Phasix™ Mesh implantation at the time of midline fascial closure compared to primary suture closure in preventing a subsequent incisional hernia in subjects at risk for incisional hernia after open midline laparotomy surgery.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/14/2024
Locations: Nebraska Medical Center, Omaha, Nebraska +1 locations
Conditions: Open Midline Laparotomy
Register for Updates
Targeted Transcranial Magnetic Stimulation to Improve Hippocampal-dependent Declarative Memory Abilities
NCT03574207
Recruiting
This is a pilot study of non-invasive transcranial magnetic stimulation (TMS) to improve memory in healthy adults. It will also examine treating memory deficits in older adults with amnestic mild cognitive impairment (aMCI), a condition that frequently precedes Alzheimer's disease (AD. The study will test whether a form of non-invasive brain stimulation repetitive transcranial magnetic stimulation (rTMS) can improve memory abilities in healthy young adults, healthy older adults, and older adults... Read More
Gender:
All
Ages:
19 years and above
Trial Updated:
03/14/2024
Locations: University of Nebraska Medical Center, Omaha, Nebraska
Conditions: Mild Cognitive Impairment, Memory Loss
Register for Updates
Phase 1 Trial of LVGN6051 as Single Agent and in Combination With Keytruda (Pembrolizumab) in Advanced or Metastatic Malignancy
NCT04130542
Recruiting
LVGN6051 is a humanized monoclonal antibody that specifically binds to CD137, and acts as an agonist against CD137. This first in human study of LVGN6051 is designed to establish the maximum tolerated dose (MTD) and/or the recommended dose for expansion (RDE) as well as the recommended Phase 2 dose(s) (RP2D) of LVGN6051, both as a single agent (monotherapy) and in combination with a fixed dose of anti-PD-1 antibody (Pembrolizumab/MK-3475) in the treatment of advanced or metastatic malignancy.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/13/2024
Locations: Nebraska Cancer Specialist, Omaha, Nebraska
Conditions: Cancer
Register for Updates
Targeted Alpha Therapy With 225Actinium-Prostate Specific Membrane Antigen (PSMA)-I&T of Castration-resISTant Prostate Cancer (TATCIST).
NCT05219500
Recruiting
The treatment regimen will consist of 4 doses of FPI-2265
Gender:
Male
Ages:
18 years and above
Trial Updated:
03/13/2024
Locations: XCancer Omaha/Urology Cancer Center, Omaha, Nebraska
Conditions: Metastatic Castration Resistant Prostate Cancer
Register for Updates
Estetrol for the Treatment of Female Sexual Arousal Disorder in Postmenopausal Women
NCT06308614
Recruiting
The goal of this clinical trial is investigating estetrol (E4) in women after menopause, suffering from sexual arousal disorder. The main question it aims to answer is: is 20 mg estetrol monohydrate effective in the treatment of sexual arousal disorder in women after their menopause. Participants will visit the clinic 7 times and complete a daily diary while receiving estetrol or placebo for 12 weeks. Placebo is a pill that looks the same as estetrol but has no active ingredient. Researchers wil... Read More
Gender:
Female
Ages:
Between 40 years and 65 years
Trial Updated:
03/12/2024
Locations: Estetra Study Site, Omaha, Nebraska
Conditions: Sexual Dysfunction, Physiological
Register for Updates
LOWER: Lomitapide Observational Worldwide Evaluation Registry
NCT02135705
Recruiting
This global product exposure registry is a multicentre, long-term, prospective, observational cohort study (exposure registry), designed to evaluate the long term safety and effectiveness of lomitapide.
Gender:
All
Ages:
All
Trial Updated:
03/11/2024
Locations: Methodist Physicians Clinic, Omaha, Nebraska
Conditions: Homozygous Familial Hypercholesterolemia
Register for Updates
Repositioning Immunotherapy in VetArans With Lung Cancer
NCT06275360
Recruiting
This study is a multicenter Phase II single arm trial to assess the safety and efficacy of chemotherapy and immunotherapy followed by radiotherapy in patients with unresectable Stage III NSCLC.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/11/2024
Locations: Omaha VA Nebraska-Western Iowa Health Care System, Omaha, NE, Omaha, Nebraska
Conditions: Non-Small Cell Lung Cancer
Register for Updates